Decision to list medical devices supplied by Shimadzu Oceania Pty Limited
What we’re doing
We are pleased to announce the approval of a listing agreement with Shimadzu Oceania Pty Limited (“Shimadzu”) for the supply of medical devices to Health New Zealand | Te Whatu Ora (“Health NZ”) hospitals in the medical imaging, software and associated products category.
In summary this will result in:
- listing of medical devices in the medical imaging, software and associated products category supplied by Shimadzu in Part III of Section H of the Pharmaceutical Schedule from 1 June 2025 under a national agreement that all Health NZ hospitals may purchase under; and
- Health NZ hospitals being able to continue to purchase other suppliers’ brands of medical imaging, software and associated products as the agreement is not for sole supply.
Any changes to the original proposal?
This decision was subject to a consultation letter dated 14 April 2025.
No changes have been made to the original proposal.
Who we think will be most interested
- Health NZ staff in a range of different clinical settings including but not limited to:
- Clinicians
- Radiology
- Nurses
- Clinical engineers and maintenance services
- Procurement and supply chain personnel
- Suppliers and wholesalers
Detail about this decision
In November 2020 New Zealand Health Partnerships, in coordination with Pharmac, released a Request for Proposals (“RFP”):
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
Pharmac has been working with suppliers who responded to the RFP to seek provisional agreements. After consulting on the provisional agreement with Shimadzu, Pharmac has decided to list Shimadzu’s medical imaging, software and associated products in Part III of Section H of the Pharmaceutical Schedule from 1 June 2025.
Health NZ hospitals can continue to choose which medical imaging, software and associated products they procure, including from other suppliers. Health NZ hospitals that procure medical imaging, software and associated products from Shimadzu must ensure they do so under the terms and conditions, including pricing, in the agreement from 1 June 2025.
Our response to what you told us
We appreciate the time people took to review this consultation. No feedback was received in relation to this consultation.
If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 660 050.